Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma
Cancers · 27.02.2025 · 17 (5) · 832
DOI: 10.3390/cancers17050832 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 27.02.2025. Verfasst von Magdalena Kuras und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, 214 28 Malmö, Sweden. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development and Innovation Fund (Hungary), Berta Kamprad Foundation, Semmelweis University grant.
Abstract (Originalsprache)
Background
Melanoma is a highly heterogeneous disease, and a deeper molecular classification is essential for improving patient stratification and treatment approaches. Here, we describe the histopathology-driven proteogenomic landscape of 142 treatment-naïve metastatic melanoma samples to uncover molecular subtypes and clinically relevant biomarkers.
Methods
We performed an integrative proteogenomic analysis to identify proteomic subtypes, assess the impact of BRAF V600 mutations, and study the molecular profiles and cellular composition of the tumor microenvironment. Clinical and histopathological data were used to support findings related to tissue morphology, disease progression, and patient outcomes.
Results
Our analysis revealed five distinct proteomic subtypes that integrate immune and stromal microenvironment components and correlate with clinical and histopathological parameters. We demonstrated that BRAF V600-mutated melanomas exhibit biological heterogeneity, where an oncogene-induced senescence-like phenotype is associated with improved survival. This led to a proposed mortality risk-based stratification that may contribute to more personalized treatment strategies. Furthermore, tumor microenvironment composition strongly correlated with disease progression and patient outcomes, highlighting a histopathological connective tissue-to-tumor ratio assessment as a potential decision-making tool. We identified a melanoma-associated SAAV signature linked to extracellular matrix remodeling and SAAV-derived neoantigens as potential targets for anti-tumor immune responses.
Conclusions
This study provides a comprehensive stratification of metastatic melanoma, integrating proteogenomic insights with histopathological features. The findings may aid in the development of tailored diagnostic and therapeutic strategies, improving patient management and outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, 214 28 Malmö, Sweden.
- Department of Biomedical Engineering, Lund University, 221 00 Lund, Sweden.
- Department of Clinical Sciences Lund, Division of Oncology, Lund University, 221 00 Lund, Sweden.
- Institute for Systems Genetics, NYU Grossman School of Medicine, New York, NY 10016, USA.
- Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY 10016, USA.
- Department of Dermatology and Allergology, University of Szeged, 6720 Szeged, Hungary.
ORCID-Profile: Magdalena Kuras, Leticia Szadai, Peter Horvatovich, Charlotte Welinder, Henrik Ekedahl, Christian Ingvar, Melinda Rezeli, Jeovanis Gil, Roger Appelqvist, Johan Malm, Aniel Sanchez, Attila Marcell Szasz, David Fenyö
Förderung
- National Research, Development and Innovation Fund (Hungary)
- Berta Kamprad Foundation
- Semmelweis University grant
- Hungarian National Research, Development and Innovation Office
- NCI NIH HHS
- Hungarian Academy of Sciences
- Semmelweis 250+ Excellence Ph.D. Scholarship
- Berta Kamprad Foundation IKEA
Zitieren
APA
Kuras, M., Betancourt, L. H., Hong, R., Szadai, L., Rodriguez, J., Horvatovich, P., Pla, I., Eriksson, J., Szeitz, B., Deszcz, B., Welinder, C., Sugihara, Y., Ekedahl, H., Baldetorp, B., Ingvar, C., Lundgren, L., Lindberg, H., Oskolas, H., Horvath, Z., …, & Marko-Varga, G. (2025). Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma. Cancers, 17(5), 832. https://doi.org/10.3390/cancers17050832
Vancouver
Kuras M, Betancourt LH, Hong R, Szadai L, Rodriguez J, Horvatovich P, et al. Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma. Cancers. 2025;17(5):832. doi:10.3390/cancers17050832
BibTeX
@article{Kuras2025,
author = {Kuras, Magdalena and Betancourt, Lazaro Hiram and Hong, Runyu and Szadai, Leticia and Rodriguez, Jimmy and Horvatovich, Peter and Pla, Indira and Eriksson, Jonatan and Szeitz, Beáta and Deszcz, Bartłomiej and Welinder, Charlotte and Sugihara, Yutaka and Ekedahl, Henrik and Baldetorp, Bo and Ingvar, Christian and Lundgren, Lotta and Lindberg, Henrik and Oskolas, Henriett and Horvath, Zsolt and Rezeli, Melinda and Gil, Jeovanis and Appelqvist, Roger and Kemény, Lajos V and Malm, Johan and Sanchez, Aniel and Szasz, Attila Marcell and Pawłowski, Krzysztof and Wieslander, Elisabet and Fenyö, David and Nemeth, Istvan Balazs and Marko-Varga, György},
title = {Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma},
journal = {Cancers},
year = {2025},
volume = {17},
number = {5},
pages = {832},
doi = {10.3390/cancers17050832}
}
EUVIMED